Dendreon Corp fka DNDNQ

[scmfinance]

Positive Barron's Article

"There are some good opportunities," says David King, manager of the Columbia Convertible Securities fund (PACIX). He's partial to a Chesapeake Energy 5¾% convertible preferred (CHKVZ), which recently traded at about $900, below its $1,000 face value, for a 6.4% current yield. The Chesapeake convert offers a lower-risk way to play a revival in natural-gas prices than the company's common shares. King also is partial to a 2?% convert from biotech company Dendreon (DNDN), recently trading below 75 cents on the dollar and a 13% yield to maturity in 2016. Dendreon developed a novel treatment for advanced prostate cancer that has had disappointing revenues. The company isn't far from cash-flow break-even and could be a takeover target."

Source: http://online.barrons.com/article/SB50001424052748704723404578207791554873144.html?mod=TWM_pastedition_1#articleTabs_article%3D1